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Introduction: Malva sylvestris is one of medicinal plants from Malvaceae family. 
According to some important Iranian traditional medicine’s references (ITMR) all 
parts of this plant can be used for treatment of “Zahir” that this disease has similar 
signs and symptoms to Ulcerative Colitis (UC). UC is one of the common types of 
Inflammatory Bowel Disease (IBD) which mostly affects distal colon and rectum in 
many new cases each year. Because of low efficacy and high adverse effect of 
today’s drugs, many refers of ITMRs, high frequency in Iran and our team’s 
previous study of several extraction from this plant on UC induction in mice, we 
decided to use aqueous extraction to prepare an oral colon specific formulation. 
Methods and Results: The fresh plant was collected from North of Fars province. 
Hydro extraction was done with maceration route in the refrigerator and out of light 
and then the concentrated extraction was lyophilized. Polysaccharides extraction was 
done with absolute acetone and poly phenolic compounds were extracted with n-
hexane and ethyl acetate. For all of total sugar evaluated with Phenol-Sulfuric acid 
method. Also Gallic acid and Folin-Ciocalteu reagents were used for determination 
of total phenolic compounds. Twelve formulations prepared and in vitro evaluations 
were done based on US Pharmacopoeia. Disintegration time test, dissolution time 
test, hardness, weight variation, content uniformity and release test were performed 
on tablets. Yield of total extraction and polysaccharides extraction were 10.83% and 
9.6% W/W. Be calculated 0.18 mg poly phenolic compounds in each 1 g of 
lyophilized extraction. Other Pharmacognosy’s tests (Linearity, intra and inter day 
accuracy and precision) and pharmaceutical tests (Hardness, weight variation and 
content uniformity of tablets) were in the acceptable range. Tablets coated with 
Eudragit S100 (E) 2% solution exhibited 7.3% release after 2 hours, 42.33% after 6 
hours and 96.21% after 10 hours. 
Conclusions:Tablets that used Malva sylvestris as active pharmaceutical ingredient 
and prepared by direct compression method and coated with E 2% solution, showed 
the most suitable results for clinical trials in UC cases. 
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